Increased number of T cells and exacerbated inflammatory pathophysiology in a human IgG4 knock-in MRL/lpr mouse model

PLoS One. 2023 Feb 10;18(2):e0279389. doi: 10.1371/journal.pone.0279389. eCollection 2023.

Abstract

Immunoglobulin (Ig) G4 is an IgG subclass that can exhibit inhibitory functions under certain conditions because of its capacity to carry out Fab-arm exchange, inability to form immune complexes, and lack of antibody-dependent and complement-dependent cytotoxicity. Although several diseases have been associated with IgG4, its role in the disease pathogeneses remains unclear. Since mice do not express an IgG subclass that is identical to the human IgG4 (hIgG4), we generated hIGHG4 knock-in (KI) mice and analyzed their phenotypes. To preserve the rearrangement of the variable, diversity, and joining regions in the IGH gene, we transfected a constant region of the hIGHG4 gene into C57BL/6NCrSlc mice by using a gene targeting method. Although the mRNA expression of hIGHG4 was detected in the murine spleen, the serum level of the hIgG4 protein was low in C57BL/6-IgG4KI mice. To enhance the production of IgG4, we established an MRL/lpr-IgG4KI mice model by backcrossing. These mice showed a high IgG4 concentration in the sera and increased populations of IgG4-positive plasma cells and CD3+B220+CD138+ T cells in the spleen. Moreover, these mice showed aggravated inflammation in organs, such as the salivary glands and stomach. The MRL/lpr-IgG4KI mouse model established in the present study might be useful for studying IgG4-related disease, IgG4-type antibody-related diseases, and allergic diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Humans
  • Immunoglobulin G
  • Immunoglobulin G4-Related Disease*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred MRL lpr
  • Spleen
  • T-Lymphocytes*

Substances

  • Immunoglobulin G

Grants and funding

Funding: This research was funded by Grants-in-Aid from 1) Search for therapeutic targets and biomarkers using tissues and blood of patients with autoimmune diseases; the Center for Innovation in Immunoregulative Technology and Therapeutics, Graduate School of Medicine, Kyoto University, 2013-2016, 2) Research on elucidation of pathogenesis and establishment of new treatments for IgG4-related diseases; the Japan Agency for Medical Research and Development, 2014-2016, 3) Research on the development of new biomarkers and therapeutic targets for IgG4-related diseases; the Japan Agency for Medical Research and Development, 2017-2019, and 4) Improvement of IgG4-related disease model human IgG4 knock-in mouse and examination of efficacy of each drug; Scientific Research, the Ministry of Education, Culture, Sports, Science and Technology, 2020-2021. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.